Equities research analysts predict that Davita Inc (NYSE:DVA) will post earnings of $0.91 per share for the current quarter, Zacks reports. Six analysts have issued estimates for Davita’s earnings. The lowest EPS estimate is $0.89 and the highest is $0.94. Davita reported earnings of $0.98 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 7.1%. The business is scheduled to issue its next earnings report on Thursday, February 15th.
According to Zacks, analysts expect that Davita will report full-year earnings of $3.42 per share for the current financial year, with EPS estimates ranging from $3.34 to $3.46. For the next year, analysts forecast that the firm will post earnings of $3.46 per share, with EPS estimates ranging from $3.22 to $3.77. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Davita.
Davita (NYSE:DVA) last released its earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). Davita had a net margin of 3.40% and a return on equity of 13.31%. The business had revenue of $3.92 billion for the quarter, compared to analysts’ expectations of $3.91 billion. During the same quarter in the previous year, the business posted $0.95 earnings per share. Davita’s revenue for the quarter was up 5.2% on a year-over-year basis.
Several research firms have recently issued reports on DVA. TheStreet upgraded shares of Davita from a “c” rating to a “b-” rating in a report on Thursday. Wolfe Research upgraded shares of Davita from a “market perform” rating to an “outperform” rating in a report on Monday, October 23rd. JPMorgan Chase & Co. lifted their target price on shares of Davita from $4.90 to $84.00 and gave the company a “strong-buy” rating in a report on Thursday, December 7th. SunTrust Banks set a $70.00 price objective on shares of Davita and gave the stock a “hold” rating in a report on Thursday, December 7th. Finally, KeyCorp restated a “hold” rating on shares of Davita in a report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Davita presently has a consensus rating of “Hold” and a consensus price target of $76.00.
Davita (NYSE:DVA) traded up $0.68 during mid-day trading on Monday, hitting $75.53. 1,929,967 shares of the stock traded hands, compared to its average volume of 2,200,000. Davita has a 1 year low of $52.51 and a 1 year high of $75.60. The stock has a market capitalization of $13,840.00, a price-to-earnings ratio of 28.94, a price-to-earnings-growth ratio of 14.93 and a beta of 0.96. The company has a quick ratio of 1.35, a current ratio of 1.40 and a debt-to-equity ratio of 1.79.
Davita announced that its board has approved a share repurchase program on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in shares. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.
In other Davita news, insider James K. Hilger sold 5,608 shares of Davita stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $69.46, for a total value of $389,531.68. Following the completion of the sale, the insider now owns 47,649 shares of the company’s stock, valued at approximately $3,309,699.54. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Charles Berg sold 7,048 shares of Davita stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $69.24, for a total transaction of $488,003.52. Following the completion of the sale, the insider now directly owns 5,359 shares of the company’s stock, valued at approximately $371,057.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 117,937 shares of company stock valued at $8,028,379. 2.10% of the stock is currently owned by insiders.
Several hedge funds have recently modified their holdings of DVA. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Davita in the 3rd quarter worth $154,000. Eqis Capital Management Inc. lifted its stake in Davita by 62.5% in the 3rd quarter. Eqis Capital Management Inc. now owns 7,473 shares of the company’s stock worth $444,000 after purchasing an additional 2,873 shares in the last quarter. Accident Compensation Corp lifted its stake in Davita by 147.5% in the 2nd quarter. Accident Compensation Corp now owns 15,100 shares of the company’s stock worth $978,000 after purchasing an additional 9,000 shares in the last quarter. Xact Kapitalforvaltning AB lifted its stake in Davita by 22.8% in the 3rd quarter. Xact Kapitalforvaltning AB now owns 19,851 shares of the company’s stock worth $1,179,000 after purchasing an additional 3,685 shares in the last quarter. Finally, Cibc World Markets Corp lifted its stake in Davita by 35.3% in the 2nd quarter. Cibc World Markets Corp now owns 22,006 shares of the company’s stock worth $1,425,000 after purchasing an additional 5,746 shares in the last quarter. 87.94% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Analysts Expect Davita Inc (DVA) Will Post Earnings of $0.91 Per Share” was published by Equities Focus and is owned by of Equities Focus. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.equitiesfocus.com/2018/01/06/analysts-expect-davita-inc-dva-will-post-earnings-of-0-91-per-share.html.
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Get a free copy of the Zacks research report on Davita (DVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.